Astal Laboratories Ltd
Astal Laboratories Ltd is engaged in Manufacturing and Trading of all kinds of active Pharmaceutical Ingredients (Bulk Drugs)
- Market Cap ₹ 284 Cr.
- Current Price ₹ 67.3
- High / Low ₹ 103 / 64.0
- Stock P/E 29.1
- Book Value ₹ 40.5
- Dividend Yield 0.00 %
- ROCE 34.8 %
- ROE 30.1 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 213% CAGR over last 5 years
- Debtor days have improved from 246 to 157 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -13.6%
- Promoter holding is low: 4.64%
- Company has high debtors of 157 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 24 | 64 | 139 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 23 | 51 | 124 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | 1 | 13 | 15 |
| OPM % | 10% | -4% | 5% | 20% | 11% | ||||||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | 0 | 1 | 12 | 13 |
| Tax % | 25% | -260% | 50% | 0% | 12% | 0% | 0% | 67% | 28% | 25% | |||
| 0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 1 | 9 | 10 | |
| EPS in Rs | 0.23 | 0.45 | 0.03 | 0.03 | -0.03 | -0.20 | -0.08 | 0.03 | -0.05 | 0.05 | 0.79 | 9.08 | 9.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 161% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 48% |
| 5 Years: | 213% |
| 3 Years: | 665% |
| TTM: | 45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 50% |
| 3 Years: | 29% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 16% |
| 3 Years: | 20% |
| Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 10 | 10 | 11 |
| Reserves | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 26 | 33 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 13 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 13 | 14 | 44 | |
| Total Liabilities | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 10 | 37 | 63 | 101 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 11 | 11 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 10 | 36 | 52 | 89 | |
| Total Assets | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 10 | 37 | 63 | 101 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -6 | -13 | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6 | -8 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 18 | 3 | |
| Net Cash Flow | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 6 | -17 |
| Free Cash Flow | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -11 | -18 |
| CFO/OP | 371% | 170% | 81% | 104% | 100% | 81% | 95% | -950% | 125% | 1,021% | -496% | -96% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 337 | 244 | 157 | ||||||||
| Inventory Days | 0 | 18 | 112 | |||||||||
| Days Payable | 197 | 82 | ||||||||||
| Cash Conversion Cycle | 0 | 337 | 65 | 187 | ||||||||
| Working Capital Days | -73 | 138 | 118 | 97 | ||||||||
| ROCE % | 2% | 1% | 1% | 0% | 0% | -2% | -1% | 0% | 0% | 1% | 8% | 35% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Interest Income (Financial/Lending Business phase) ₹ Lacs |
|
|||||||||||
| Number of Owned Pharmaceutical Plants Number |
||||||||||||
| Number of Permanent Employees Number |
||||||||||||
| Reliance on Third-Party Manufacturing Binary (1=Yes, 0=No) |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Submitted RTA certificate under Regulation 74(5) for quarter ended 31 March 2026.
- Closure of Trading Window 31 Mar
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 20 Mar
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
19 Mar - Received Form C (Reg.7(2)) on 19-Mar-2026: promoter ACESO Research Labs LLP purchased shares.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Feb
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company used to have a departmental store at Kanpur and a saddlery export business. Company used to sell company bridles, halters, rugs, saddles, strip leather, reins, shoes and bell boots, etc. But due to unavoidable circumstances, business was closed down. Afterwards, company entered in real estate business.